Physician profile
Patrick A Beiter
NPI 1851479877
$4,096.24
in general payments reported to CMS, 2019-2025
37 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $235 · 2021: $11.54 · 2022: $447 · 2023: $558 · 2024: $883 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,495.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $721.60 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $686.88 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Dexcom, INC. | $317.80 | 2022-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Phathom Pharmaceuticals, INC. | $250.99 | 2024 | Voquezna |
| Novo Nordisk INC | $232.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.62 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $180.97 | 2021-2025 | Watchman Flx, Watchman Access System |
| Abbvie INC. | $171.59 | 2019-2025 | |
| Daiichi Sankyo INC. | $154.93 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $118.91 | 2019 | |
| Pfizer INC. | $110.10 | 2019-2025 | |
| Allergan, INC. | $90.96 | 2019-2020 | |
| Gilead Sciences, INC. | $90.73 | 2025 | Yeztugo |
| Janssen Pharmaceuticals, INC | $76.92 | 2019-2020 | |
| Lilly USA, LLC | $72.32 | 2019-2025 | Zepbound, Mounjaro |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $67.03 | 2019 | |
| Amgen INC. | $59.65 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $48.91 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $47.29 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.98 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $39.31 | 2019-2025 | Ajovy |
| Therapeuticsmd, INC. | $33.98 | 2022 | |
| Exact Sciences Corporation | $32.22 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.12 | 2025 | Caplyta |
| Acadia Pharmaceuticals INC | $27.90 | 2025 | Nuplazid |
| Astellas Pharma US INC | $22.30 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $22.01 | 2019 | |
| Tersera Therapeutics LLC | $21.16 | 2023 | Zoladex |
| Bayer Healthcare Pharmaceuticals INC. | $19.17 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $18.06 | 2025 | Uptravi, Opsumit |
| Cranial Technologies, INC | $17.14 | 2020 | |
| Ironwood Pharmaceuticals, INC | $15.46 | 2019 | |
| Genentech USA, INC. | $14.79 | 2019 | |
| Sanofi Pasteur INC. | $12.86 | 2019 | |
| Medtronic USA, INC. | $11.90 | 2019 | |
| Glaxosmithkline, LLC. | $11.67 | 2019 | |
| Shire North American Group INC | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Beiter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.